ライフサイエンスコーパス: disease-free survival

1 Primary outcome was 3-year disease-free survival.

2 of pooled analysis were overall survival and disease-free survival.

3 ositive tumor cells correlate with shortened disease-free survival.

4 ost significant factor affecting overall and disease-free survival.

5 specific gene expression was associated with disease-free survival.

6 regimen improved CAR-T cell persistence and disease-free survival.

7 CFTR was significantly associated with poor disease-free survival.

8 ge B-cell lymphoma (DLBCL) achieve prolonged disease-free survival.

9 atin chemoresistance associated with reduced disease-free survival.

10 toxicity, overall survival (OS), and distant disease-free survival.

11 nalysis showed no significant differences in disease-free survival.

12 c genes, whose expression is associated with disease-free survival.

13 ategies that mitigated toxicity and improved disease-free survival.

14 mor recurrence, metastatic foci, and reduced disease-free survival.

15 Our primary end point was disease-free survival.

16 vent acquired drug resistance and to prolong disease-free survival.

17 ed both progression-free survival and 1-year disease-free survival.

18 teristics, and overall survival and invasive disease-free survival.

19 nces in clinical and pathologic features and disease-free survival.

20 oregional disease-free survival, and distant disease-free survival.

21 long-term outcomes, including recurrence and disease-free survival.

22 The primary end point was invasive disease-free survival.

23 zed breast cancer (LOC group) with long-term disease-free survival.

24 ar results were observed for both groups for disease-free survival.

25 sulting in high rates of ocular survival and disease-free survival.

26 The secondary outcome was disease-free survival.

27 n KCNQ1:KCNE3 channel complex expression and disease-free survival.

28 cholesterolemia, is associated with improved disease-free survival.

29 rimidines, although the effect was mainly on disease-free survival.

30 ur 10-15 cm from the anal verge had improved disease-free survival (0.59, 0.40-0.85; p=0.005, p(inter

31 p=0.004) but did not significantly increase disease-free survival (0.80 [0.63-1.01]; p=0.06).

32 ar overall survival (P = 0.0002) and shorter disease-free survival 5-year (P = 0006).

33 ith the R-CHOP arm, the R-HDS arm had better disease-free survival (79% v 91%, respectively; P = .034

34 resent secondary patient outcomes, including disease-free survival, a specified endpoint by protocol,

35 The primary end point was disease-free survival, according to blinded independent

36 Meier survival analysis, 1-, 5-, and 10-year disease-free survival after liver transplant was 93%, 82

37 Proportion of patients who achieved pCR and disease-free survival after neoadjuvant treatment accord

38 he stratification factors were disease site, disease-free survival after primary therapy or primary s

39 including E2A-PBX1 leukemias, and increased disease-free survival after secondary transplantation.

40 itor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant t

41 significantly improved the rates of invasive-disease-free survival among patients with HER2-positive,

42 ed in the intention-to-treat population) and disease-free survival (analysed in patients who had surg

43 endpoint of the 5-year analysis was invasive disease-free survival, analysed by intention to treat.

44 The primary endpoint was disease-free survival, analysed by the intention-to-trea

45 rs resulted in significantly higher rates of disease-free survival and a lower incidence of contralat

46 ith clinical endpoints reflecting overall or disease-free survival and a pathologic complete response

47 Disease-free survival and distant disease-free survival

48 anscript levels were associated with shorter disease-free survival and higher tumor grade.

49 ifen or with an aromatase inhibitor improved disease-free survival and improved freedom from breast c

50 rable AML according to European LeukemiaNet, disease-free survival and OS were significantly improved

51 and PB-MRD response ( P = .024 and .027 for disease-free survival and OS, respectively).

52 Times of disease-free survival and overall survival did not diffe

53 Kaplan-Meier analysis of disease-free survival and overall survival was performed

54 duced a significant result only for BMI (for disease-free survival and overall survival, adjusted haz

55 Intent-to-treat analyses were done for disease-free survival and overall survival.

56 Primary outcomes were disease-free survival and overall survival.

57 iocytosis (LCH), which historically has poor disease-free survival and poor overall survival.

58 is a prerequisite for long-term unmaintained disease-free survival and potential for cure.

59 erapies, BRAF inhibitors improve overall and disease-free survival and speed the recovery of symptoma

60 Secondary end points included disease-free survival and the cumulative rate of nonsent

61 The primary endpoint was disease-free survival and the trial aimed to detect 5% d

62 Ocular survival, disease-free survival and time to regression of seeds we

63 gh IL17 expression was associated with lower disease-free survival and worse prognosis in IDC patient

64 xpression level is related to a shorter DFS (disease free survival) and OS (overall survival), servin

65 Primary endpoint is disease-free survival, and analyses are in the intention

66 disease-free survival, isolated locoregional disease-free survival, and distant disease-free survival

67 tio is associated with lower survival, lower disease-free survival, and higher risk of relapse in pat

68 For MALT lymphomas, local control, disease-free survival, and overall survival are good wit

69 iation with respect to 5-year local control, disease-free survival, and overall survival.

70 st cancer-free interval (primary end point), disease-free survival, and overall survival.

71 we report 5-year progression-free survival, disease-free survival, and safety.

72 Ocular survival, disease-free survival, and time to regression of seeds.

73 Two-year posttransplant survival, disease-free survival, and TRM were 68.8% +/- 6.0%, 67.6

74 The primary outcome was invasive disease-free survival, as defined in the original protoc

75 The primary endpoint was 3-year disease-free survival, assessed in the intention-to-trea

76 and 53% (33-85%), respectively, whereas the disease-free survival at 1 and 5 years was 94% (95% CI,

77 The overall and disease-free survival at 1 year was 78% and 67% and at 2

78 The primary endpoint was disease-free survival at 10 years of follow-up.

79 Disease-free survival at 10 years was 67% (95% CI 65-69)

80 The primary end point was disease-free survival at 2 years after HSCT.

81 Disease-free survival at 3 years did not differ between

82 roscopic hysterectomy resulted in equivalent disease-free survival at 4.5 years and no difference in

83 Progression-free survival and disease-free survival at 5-year follow-up show large and

84 ought to determine whether there is improved disease-free survival benefit to taking the active drug

85 he TEXT and SOFT trials showed a significant disease-free survival benefit with exemestane plus ovari

86 The primary objective was to compare disease-free survival between each experimental group an

87 ional (TEAM) trial reported no difference in disease-free survival between exemestane monotherapy and

88 ial aimed to detect 5% differences in 5-year disease-free survival between the treatment groups.

89 ee time-to-event end points were considered: disease-free-survival, breast cancer-free interval, and

90 Invasive disease-free survival, but not OS, was significantly sup

91 The primary end point was disease-free survival by intention to treat.

92 Deep remission and prolonged disease-free survival can be achieved with first-line ch

93 To evaluate conditional disease-free survival (CDFS) for patients who underwent

94 score of 2 or less had a much better 5-year disease-free survival compared to those having a score o

95 se of intermittent letrozole did not improve disease-free survival compared with continuous use of le

96 e MAGE-A3 immunotherapeutic did not increase disease-free survival compared with placebo in patients

97 east cancer significantly improves long-term disease-free survival, compared with observation.

98 ed 5-year event-free survival (EFS), distant disease-free survival (DDFS), overall survival (OS), and

99 Disease-free survival, defined as time from randomizatio

100 the strongest predictor of overall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, resp

101 , we aimed to develop a new model to predict disease free survival (DFS) after surgical removal of pr

102 by accounting for the changing likelihood of disease-free survival (DFS) according to time elapsed af

103 The primary end point was disease-free survival (DFS) after a median of 5 years of

104 Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival

105 herapy (CCRT) could meaningfully improve 2-y disease-free survival (DFS) and disease-specific surviva

106 Disease-free survival (DFS) and metastasis-free survival

107 Disease-free survival (DFS) and OS of patients included

108 ions with HER2 protein, clinical outcomes by disease-free survival (DFS) and overall survival (OS) an

109 ety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in

110 s: Associations between these biomarkers and disease-free survival (DFS) and overall survival (OS) we

111 Disease-free survival (DFS) and overall survival (OS) we

112 Disease-free survival (DFS) and overall survival (OS) we

113 Primary end points were disease-free survival (DFS) and overall survival (OS).

114 Efficacy end points were disease-free survival (DFS) and overall survival (OS).

115 II colon cancer and the prognostic effect on disease-free survival (DFS) and overall survival (OS).

116 all survival (OS); secondary end points were disease-free survival (DFS) and specific DFS (SDFS).

117 all survival (OS); secondary end points were disease-free survival (DFS) and specific DFS (SDFS).

118 resulted in a significant decrease in RR and disease-free survival (DFS) for patients with higher CD3

119 The primary endpoint of disease-free survival (DFS) for ymrEMVI and ypEMVI was c

120 rimary end point of the study was to improve disease-free survival (DFS) from 14 to 18 months by addi

121 With 3,250 patients, a disease-free survival (DFS) hazard ratio of 0.82 for eac

122 a meta-analysis of overall survival (OS) and disease-free survival (DFS) in 6042 patients from four c

123 Median disease-free survival (DFS) in the entire cohort was 21.

124 We assessed if biochemical disease-free survival (DFS) is improved by adding 6 mont

125 The disease-free survival (DFS) of patients with MDM2rs22797

126 However, disease-free survival (DFS) over time is dynamic and cha

127 val (OS), MCC-specific survival (MCCSS), and disease-free survival (DFS) relationships in a cohort of

128 ) that treatment with H-RT results in 5-year disease-free survival (DFS) that is not worse than C-RT

129 d recurrence of the IPMN, and 5- and 10-year disease-free survival (DFS) was 82% and 78%, respectivel

130 Five-year overall survival (OS) and disease-free survival (DFS) was worse for all categories

131 Similarly, 5-yr/10-yr OS and disease-free survival (DFS) were better in group PLT ver

132 ors (78% vs 28%, P < 0.001).Overall (OS) and disease-free survival (DFS) were both greater after tumo

133 Operative mortality and morbidity, and disease-free survival (DFS) were calculated.

134 Overall survival (OS) and disease-free survival (DFS) were evaluated among a 52-we

135 The secondary endpoints were toxicity, disease-free survival (DFS), and overall survival at 1 y

136 The primary end point was 5-year disease-free survival (DFS), and the key secondary end p

137 ed for the end points overall survival (OS), disease-free survival (DFS), nonrelapse mortality (NRM),

138 ondary endpoints were overall survival (OS), disease-free survival (DFS), R0 resection rates, sphinct

139 In multivariable models for disease-free survival (DFS), significant interactions be

140 nt adjuvant sunitinib trial showing improved disease-free survival (DFS), the appropriate strategy fo

141 The primary end point was disease-free survival (DFS), which included invasive rec

142 stoma and to assess its prognostic effect on disease-free survival (DFS).

143 The primary outcome was disease-free survival (DFS).

144 The primary end point was disease-free survival (DFS).

145 t least 1 menstrual cycle), pregnancies, and disease-free survival (DFS).

146 (2 of 28 patients) and overall had a longer disease-free survival (DFS; 190.1 vs. 100.2 months; P <

147 noma-specific survival (MSS; P = .0025), and disease-free survival (DFS; P = .0466).

148 the instantaneous hazard of recurrence (ie, disease-free survival [DFS]) stratified by anti-HER2 Th1

149 rence, 3- or 5-year overall survival(OS) and disease free survival(DFS) between the two approaches.

150 Disease-free survival did not differ significantly betwe

151 nown clinicopathologic and biologic factors, disease-free survival, distant metastasis-free survival,

152 ession with breast cancer-specific survival, disease-free survival, distant relapse-free survival, pa

153 Ocular survival, disease-free survival, ERG: peak-to-peak ERG amplitudes

154 stuzumab significantly reduced the risk of a disease-free survival event (HR 0.76, 95% CI 0.68-0.86)

155 3045 patients in the sequential group had a disease-free survival event.

156 median follow-up 10 years [IQR 10-10]), 1087 disease-free survival events and 914 deaths had occurred

157 At 2 year follow-up, 70 invasive disease-free survival events had occurred in patients in

158 tinib group had significantly fewer invasive disease-free survival events than those in the placebo g

159 The primary endpoint was 3-year disease-free survival for all eligible patients (intenti

160 ghly predictive of treatment outcome; 5-year disease-free survival for MRD-negative patients (n = 125

161 One year probabilities of overall and disease-free survival for the entire cohort, including p

162 The estimated 3-year disease-free survival for the intention-to-treat group w

163 The primary endpoint was non-regrowth disease-free survival from the date that chemoradiothera

164 ohorts of up to 301 cases into good and poor disease-free survival groups (14VF HR = 2.4, 14GT HR = 3

165 on was independently associated with shorter disease-free survival (Hazard Ratio (HR) for relapse 3.5

166 urvival (hazard ratio = 3.19; P = 0.013) and disease-free survival (hazard ratio = 2.60; P = 0.001).

167 ng endocrine therapy was related to improved disease-free-survival (hazard ratio [HR], 0.79; 95% CI,

168 t chemotherapy did not significantly improve disease-free survival (HR 0.91, 95% CI 0.77-1.07; p=0.23

169 onic acid was associated with lower invasive-disease-free survival (HR 2.47, 95% CI 1.23-4.97) and ov

170 HR, 8.41; 95% CI: 6.7-11; p = 0.02), reduced disease-free survival (HR, 0.12; 95% CI: 0.12-0.74; p =

171 00; 95% CI, 0.78 to 1.28; P = 1.00), distant disease-free survival (HR, 1.12; 95% CI, 0.86 to 1.47; P

172 lity (NRM) (HR, 1.50; P < .01), and inferior disease-free survival (HR, 1.41; P = .02).

173 etic stem cell transplantation had increased disease-free survival (HR, 7.2; 95% CI: 1.6-33; p = 0.01

174 vival: HR, 0.37; 95% CI, 0.15-0.93; invasive disease-free survival: HR, 0.58; 95% CI, 0.34-1.01; all

175 he TaxAC regimens was planned, with invasive disease-free survival (IDFS) as the primary end point.

176 its high expression correlates with adverse disease free survival in clinical samples.

177 ndent prognostic factor for poor overall and disease free survival in patients with CRC (p = 0.007).

178 lable for overall survival in 1186 patients, disease-free survival in 1184, and distant recurrence-fr

179 ression correlated positively with increased disease-free survival in antiestrogen-treated breast can

180 excellent treatment that provides long-term disease-free survival in children diagnosed with advance

181 quality of life, secondary malignancies, and disease-free survival in CR/CRu patients.

182 confers no therapeutic advantage in terms of disease-free survival in early breast cancer, although i

183 al replication stress in vitro and long-term disease-free survival in mice with B-ALL, without detect

184 induction of T-cell immunity correlates with disease-free survival in patients treated for high-grade

185 brafish thyroid cancer that is predictive of disease-free survival in patients with papillary thyroid

186 After 35 months median follow-up, 3-year disease-free survival in patients with RS </= 11 and end

187 a tumor suppressor gene associated with poor disease-free survival in prostate cancer.

188 vestigated whether bevacizumab could improve disease-free survival in the adjuvant setting after rese

189 associated with better overall survival and disease-free survival in the combination of both cohorts

190 , MAF status was not prognostic for invasive-disease-free survival in the control group (MAF-positive

191 broken up into three co-primary objectives: disease-free survival in the overall population, the no-

192 age I/II, or stage III/IV disease and poorer disease-free survival in those with stage I/II disease.

193 This co-therapy significantly improves disease-free survival in vivo compared with either thera

194 significantly improves overall survival and disease-free survival in women with HER2-positive early

195 of 9 vascular features (9VF) that predicted disease-free-survival in a discovery cohort (n = 64, HR

196 This disease-free survival is longer than twice the average t

197 Secondary outcomes were disease-free survival, isolated locoregional disease-fre

198 TK inhibitors, and in most cases, long-term disease-free survival may only be achievable with alloge

199 vaccine, thereby accounting for the improved disease-free survival observed with combination therapy.

200 thological classification and post-treatment disease-free survival of patients with adenocarcinoma of

201 c-Jun mRNA level was associated with shorter disease-free survival of patients with TNBC.

202 moter methylation negatively correlated with disease-free survival of prostate cancer patients.

203 Disease-free survival of the patients was classified acc

204 Five-year disease-free survival on Kaplan-Meier analysis was 82%,

205 varied across the trials analysed: two used disease-free survival, one used progression-free surviva

206 nd RS were univariate prognostic factors for disease-free survival; only nodal status, both central a

207 ither capecitabine nor gemcitabine increased disease-free survival or overall survival.

208 emotherapy did not improve overall survival, disease-free survival, or distant recurrences.

209 breast cancer-specific survival and invasive disease-free survival (OS: HR, 0.45; 95% CI, 0.21-0.96;

210 ears of adjuvant trastuzumab did not improve disease free-survival outcomes compared with 1 year of t

211 Few randomized trials have compared disease-free survival outcomes for surgical approaches.

212 ry end points included investigator-assessed disease-free survival, overall survival, and safety.

213 covariate for overall survival and invasive disease-free survival (P < .001).

214 was associated with significantly prolonged disease-free survival (P < 0.001) and overall survival (

215 = 0.0354), the stage (P < 0.0001), and poor disease-free survival (P = 0.003).

216 men in the goserelin group also had improved disease-free survival (P=0.04) and overall survival (P=0

217 that overall survival (P=1.91 x 10(-5)) and disease-free survival (P=4.9 x 10(-5)) was poorer for TC

218 rs is correlated with poor clinical outcome (disease-free survival: P = 0.03; overall survival: P = 0

219 ls was inversely associated with overall and disease-free survival, predominantly among participants

220 Outcomes were overall survival, disease-free survival, progression-free survival, and ad

221 Outcomes included overall survival, disease-free survival, progression-free survival, and ad

222 , local recurrence (4% vs 5%, P = 0.98), and disease-free survival rate (72% vs 68%, P = 0.63) betwee

223 median follow-up of 67 months, the estimated disease-free survival rate at 5 years was 86.6% in the t

224 The disease-free survival rate difference was 0.3% (favoring

225 Tissue microarray analysis showed that the disease-free survival rate for patients with high-expres

226 The 24-month disease-free survival rate from time of CR was 90.9% in

227 We assumed a 3-year invasive-disease-free survival rate of 91.8% with pertuzumab and

228 The 2-year invasive disease-free survival rate was 93.9% (95% CI 92.4-95.2)

229 The 5-year disease-free survival rate was 95% (95% confidence inter

230 at AYA patients have improved outcomes, with disease-free survival rates of 60% to 70%, when treated

231 Disease-free survival rates of patients with MMR-deficie

232 ata have shown no significant differences in disease-free survival rates or overall survival rates be

233 ontrol rates to be 93.1%; 5-year and 10-year disease-free survival rates to be 75.7% and 71.0%, respe

234 Five-year disease-free survival rates were 39% in the FU plus LV a

235 of initial resection, ITT 5-year overall and disease-free survival rates were 69% and 60%, respective

236 Disease-free survival rates were 74.8% in the laparoscop

237 urrence rate was 4% and overall survival and disease-free survival rates were 83% and 70% at 5 years,

238 However, the 10-y disease-free survival rates were better for the SLNB gro

239 homas (884 patients), the 5-year and 10-year disease-free survival rates were reported to be 86.4% an

240 The overall survival and disease-free survival rates were significantly worse for

241 BRCA1 and BRCA2 alterations showed elevated disease-free survival rates when carboplatin was added (

242 The ATG had no impact on overall survival, disease-free survival, relapse, and nonrelapse mortality

243 condary end points were overall survival and disease-free survival, respectively.

244 Disease-free survival results were consistent with progr

245 Predefined secondary endpoints were disease-free survival, serum asparaginase activity, and

246 Secondary end points were the rates of disease-free survival, survival free from distant diseas

247 tive-surgery group also had a higher rate of disease-free survival than those in the therapeutic-surg

248 nic acid was associated with higher invasive-disease-free survival than was control treatment (HR 0.7

249 The primary endpoint was disease-free survival; the secondary endpoint, invasive-

250 lymphoma (HL) treatment have led to improved disease-free survival, this has been accompanied by an i

251 ents and found an association with increased disease-free survival time in patients treated with endo

252 had a relatively favorable 79% +/- 5% 5-year disease-free survival vs 39% +/- 7% for those with MRD >

253 Although the observed 3-year disease free survival was not as high as anticipated, ou

254 Median disease-free survival was 170 months in the absence of n

255 In arms A and B, respectively, 5-year disease-free survival was 31.2% and 16.2%, event-free su

256 Median disease-free survival was 5.8 years (IQR 1.6-8.2) for su

257 nts who did not receive chemotherapy, median disease-free survival was 58.0 months (95% CI 56.6-not r

258 The median duration of disease-free survival was 6.8 years (95% confidence inte

259 In the overall population, median disease-free survival was 60.5 months (95% CI 57.2-not r

260 The rate of disease-free survival was 72.1% in the nodal-irradiation

261 survival was 63.3% (95% CI, 54.2% to 71.0%), disease-free survival was 72.4% (95% CI, 63.0% to 79.7%)

262 , 0.80 to 1.00; P=0.04), the rate of distant disease-free survival was 78.0% versus 75.0% (hazard rat

263 The 10-year disease-free survival was 80.2% in the SLND alone group

264 At 4.5 years of follow-up, disease-free survival was 81.3% in the TAH group and 81.

265 months (95% CI, 48 to 60 months) the 5-year disease-free survival was 82% (95% CI, 77% to 89%), and

266 The 5-year BCF disease-free survival was 85% in both arms (hazard ratio

267 a median follow-up of 60 months (IQR 53-72), disease-free survival was 85.8% (95% CI 84.2-87.2) in th

268 [HR], 0.86; 95% CI, 0.64 to 1.15; P = .312); disease-free survival was 85.8% versus 91.0% (HR, 0.59;

269 5-year disease-free survival was 90% (95% CI 86-94) for patient

270 The 5-year invasive disease-free survival was 90.2% (95% CI 88.3-91.8) in th

271 ositive disease, the 3-year rate of invasive-disease-free survival was 92.0% in the pertuzumab group,

272 egative disease, the 3-year rate of invasive-disease-free survival was 97.5% in the pertuzumab group

273 iation of the expression of these genes with disease-free survival was analyzed by Cox regression ana

274 Neither overall survival (OS) nor disease-free survival was associated with IHC positivity

275 Neither OS nor disease-free survival was associated with PCR positivity

276 Association with 5-year disease-free survival was evaluated using Cox proportion

277 Disease-free survival was examined using Kaplan-Meier cu

278 magnitude of trastuzumab benefit on distant disease-free survival was higher for increasing expressi

279 Disease-free survival was higher in patients with the CC

280 5% [62-67] in the control group), and median disease-free survival was not reached (adjusted hazard r

281 Disease-free survival was not reported for these 2 studi

282 ce after nephrectomy, the median duration of disease-free survival was significantly longer in the su

283 The rate of disease-free survival was slightly higher in the dissect

284 e survival; the secondary endpoint, invasive-disease-free survival, was the primary disease endpoint

285 ar cumulative incidence of relapse (CIR) and disease-free survival were 36% and 60% for gHiR patients

286 Estimates of 10-year disease-free survival were 63% for observation, 69% for

287 The rates of disease-free survival were 82.0% in the nodal-irradiatio

288 he estimates of the 3-year rates of invasive-disease-free survival were 94.1% in the pertuzumab group

289 aplan-Meier estimates of ocular survival and disease-free survival were 94.2% (95% confidence interva

290 overall, CRC-specific, recurrence-free, and disease-free survival were analyzed.

291 overall, CRC-specific, recurrence-free, and disease-free survival were analyzed.

292 Ocular survival and disease-free survival were estimated using Kaplan-Meier

293 using cumulative incidence, and overall and disease-free survival were estimated using the Kaplan-Me

294 Disease-free survival and distant disease-free survival were improved, and breast-cancer m

295 roup), no differences in 3-year non-regrowth disease-free survival were noted between watch and wait

296 The 18-month Kaplan-Meier estimates of disease-free survival were significantly worse for the O

297 fections, nonrelapse mortality, relapse, and disease-free survival were similar in the Treg recipient

298 Median overall and disease-free survivals were significantly better in the

299 onths significantly improved 2-year invasive disease-free survival when given after chemotherapy and

300 The primary outcome was disease-free survival, which was measured as the interva